Limiting the Spread

Tracking Resistance

Improving Stewardship

Developing New Solutions

The European Commission (EC) adopted a new One Health action plan against antimicrobial resistance (AMR) in June 2017. There are three key objectives to the plan:

1. Make the EU a best practice region through better evidence, coordination, and surveillance
2. Boost research, development and innovation in order to control the spread of AMR
3. Shape the global agenda on AMR and the related risks

The EC recognizes that diagnostics are crucial for differentiating between bacterial and viral infections and identifying AMR, so that the most appropriate treatment can be given in a timely manner. Thus, the EC has stated that they will:

  • Support research into the development of new diagnostics tools in particular on-site tests in human and animals to guide practitioners regarding the use of antimicrobials
  • Support the use of IT solutions in developing tools for diagnosing human and animal infections
  • Encourage the uptake of diagnostics in medical and veterinary practice, e.g. through innovation procurement.

The full report can be viewed here.

Reference: European Commission. A European One Health Action Plan against Antimicrobial Resistance (AMR). June 29, 2017.


The differences in activity among new β-lactam/β-lactamase inhibitor combinations creates challenges for many clinicians and it will become increasingly important for microbiology laboratories to be able to produce meaningful results that will aid in the appropriate choice of these new agents. However, microbiology laboratories have few options available to determine the susceptibility of organisms to these novel antimicrobial agents as few of them are yet available on commercial AST platforms.1 Disk diffusion is the only option for testing some of these new drugs, but disks are often difficult to get. Clinical microbiology laboratories face a dilemma when it comes to providing information about the susceptibility or resistance of bacterial isolates to ceftazidime/avibactam and ceftolozane/tazobactam.

Read more

1. Humphries RM, Hindler JA. Emerging Resistance, New Antimicrobial Agents... but No Tests! The Challenge of Antimicrobial Susceptibility Testing in the Current US Regulatory Landscape. Clin Infect Dis. 2016 Jul 1;63(1):83-8.

Only when healthcare providers are able to identify whether an infection is present and if it is drug resistant in minutes rather than days, will we be able to move beyond empiric therapy. On-demand molecular diagnostics have the potential to do just that. Innovative new, on-demand diagnostics will help prevent the inappropriate use and overuse of antimicrobials and preserve our antibiotic weapons now and in the future.


If the world is serious about tackling the threat of drug-resistant infections, we need to fully embrace the step-change in technology that rapid point-of-care diagnostics represent.”

- Lord Jim O’Neil Rapid Diagnostics: Stopping Unnecessary Use of Antibiotics - The Review on Antimicrobial Resistance (2015)


Cepheid’s groundbreaking and innovative development pipeline aims to stay ahead of drug resistance and provide better stewardship solutions


Note:Slide the table to see more data

Available Now



  • Group A Strep
  • Xpress Flu/RSV
    (CLIA Waived)
  • Xpress Group A Strep
    (CLIA Waived)
  • Vaginitis/Vaginosis
  • Xpress CT/NG
    (CLIA Waived)
  • Xpress
    (CLIA Waived)
  • GI Panel

* Projected menu; subject to change.

O’Neill, J. Rapid Diagnostics: Stopping Unnecessary Use of Antibiotics - The Review on Antimicrobial Resistance. October, 2015.

© 2018 Cepheid.